Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes.

Allan Lançon, Nathalie Hanet, Brigitte Jannin, Dominique Delmas,
Jean-Marie Heydel, Gérard Lizard, Marie-Christine Chagnon, Yves Artur,
Norbert Latruffe

► To cite this version:

Allan Lançon, Nathalie Hanet, Brigitte Jannin, Dominique Delmas, Jean-Marie Heydel, et al.. Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes.. Drug Metabolism and Disposition, 2007, 35 (5), pp.699-703. 10.1124/dmd.106.013664 . hal-00259260

HAL Id: hal-00259260

<https://hal.science/hal-00259260>

Submitted on 13 Mar 2008

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESVERATROL IN HUMAN HEPATOMA HEPG2 CELLS: METABOLISM AND INDUCIBILITY OF DETOXIFYING ENZYMES

Allan Lançon¹, Nathalie Hanet², Brigitte Jannin¹, Dominique Delmas¹, Jean-Marie Heydel², Gérard Lizard¹, Marie-Christine Chagnon², Yves Artur² and Norbert Latruffe¹

¹Biochimie Métabolique et Nutritionnelle - Université de Bourgogne
Faculté des Sciences et Centre de Recherche INSERM U866, Dijon, France

²Unité Mixte de Recherche 1234 Toxicologie Alimentaire
Institut National de la Recherche Agronomique-Université de Bourgogne, Dijon, France

Running title page : Resveratrol metabolism in human liver-derived HepG2 cells

Abbreviations: HPLC, high-performance liquid chromatography; APCI-MS: atmospheric pressure chemical ionization-mass spectrometry; UGT: uridine diphosphate glucuronosyltransferase; ST: sulfotransferase; MDR: multi-drug resistance; MRP: multi-drug resistance-associated protein; RT-PCR: reverse transcriptase polymerase chain reaction.

ABSTRACT

trans-Resveratrol is a polyphenol present in several plant species. Its chemopreventive properties against several diseases have been largely documented. To validate a model for the study of the factors influencing its biological fate at the hepatic level, the metabolism and the efflux of resveratrol were studied in the human hepatoblastoma cell line, HepG2. Comparative high-performance liquid chromatography analysis of cell culture media before and after deconjugation showed that resveratrol was rapidly conjugated; at the concentration of 10 μ M, it was entirely metabolized at 8 h of incubation. Two main resveratrol metabolites, monosulfate and disulfate, were identified by atmospheric pressure chemical ionization-mass spectrometry, thanks to their quasi-molecular ion and their characteristic fragmentation. To correlate with the auto-induction of resveratrol metabolism evidenced in HepG2 cells after a pretreatment for 48 h with 10 μ M resveratrol, the inducibility of phase II enzymes by resveratrol was studied by real-time quantitative reverse transcriptase-polymerase chain reaction and flow cytometry. Observed, in particular, were an increase in mRNA expression levels of three metabolizing enzymes, two isoforms of UDP-glucuronosyltransferases, UGT1A1 and UGT2B7 (5-fold increased), and a sulfotransferase, ST1E1, in cells pretreated for 24 h with 10 μ M resveratrol. These results were correlated with an increase in protein expression, especially after 48 h of treatment. On the other hand, the intracellular resveratrol retention in cells treated with MK571 (3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoyl-ethylsulfanyl)methylsulfanyl] propionic acid), a multidrug resistance-associated protein inhibitor, strongly suggests the involvement of this ABC transporter family in the efflux of resveratrol conjugates from human liver.

Trans-resveratrol (*trans*-3,5,4'-trihydroxystilbene, fig. 1) is a natural molecule present in several vegetal sources. Its name refers to *Veratrum grandiflorum*, one of these sources. Resveratrol is also present in root preparations of *Polygonum cuspidatum*, which were used in traditional Chinese and Japanese medicines, so-called "Hu-Chang" and "Ko-jo-kon" respectively. The potential resveratrol benefits for health have led to many reports. Resveratrol may have particularly chemopreventive effects against cardiovascular diseases and ageing (for a review, see Delmas et al., 2005). It may have also chemopreventive and therapeutic properties for fighting cancer (for a review, see Delmas et al., 2006). A good knowledge of bioavailability is necessary to assess the benefits of resveratrol dietary consumption and/or resveratrol supplementation. Several studies have been reported about

metabolism and bioavailability of resveratrol in the last 5 years (for a review, see Wenzel and Somoza, 2005). Transport mechanism in human intestine was studied in Caco-2 model (Kaldas et al., 2003). In humans, it was shown that ^{14}C - resveratrol is rapidly absorbed after oral consumption. The highest plasma concentrations are reached between 30 and 60 min after ingestion, with the appearance of new resveratrol plasma peak 6 h after oral consumption. This second peak suggests the involvement of enterohepatic recirculation of conjugated metabolites by reabsorption after intestinal hydrolysis of conjugates (Walle et al., 2004), already evidenced by Marier et al. (2002) in a linked-rat model.

Our purpose was to validate the HepG2 cell line as a model for the study of the human hepatic metabolism of resveratrol. Indeed, liver constitutes an important step before the distribution of resveratrol to tissues and it is probably exposed again to resveratrol during enterohepatic recirculation, so that it plays a pivotal role in resveratrol disposition. We have already reported that hepatic uptake of resveratrol occurs according both passive diffusion and facilitated processes (Lançon et al., 2004). In the present study, we showed by HPLC analysis of culture media after deconjugation that resveratrol was rapidly conjugated and eliminated from the HepG2 cells. Metabolites were identified by mass spectrometry. Moreover, we have found that like other dietary compounds resveratrol can induce some phase II enzymes. Finally, a transport study with labeled resveratrol strongly suggested the involvement of multi-drug transporters in the efflux of conjugated resveratrol.

METHODS

Chemicals. *Trans*-resveratrol, carbamazepin and β -glucuronidase (type HP-2) were purchased from Sigma (St. Louis, MO, USA). MK571 was purchased from Alexis (San Diego, CA, USA). [^3H]-*trans*-resveratrol (specific activity: 74 GBq/mmol) labeled in ortho and para of phenol groups was prepared for us by Amersham Pharmacia Biotech (Little Chalfont, Buckinghamshire, UK).

Cell Culture and resveratrol treatments. The HepG2 cell line obtained from the European Collection of Cell Cultures was cultured in a phenol red-free DME medium supplemented with 1% glutamine, 1% non-essential L-aminoacids (Sigma) and 10% fetal bovine serum FBS (Gibco). Resveratrol was dissolved in ethanol; control and treated cells received the same final concentration of ethanol (0.1 %). For RT-PCR experiments, cells were harvested at the same time and total RNA was prepared using Trizol Reagent (Invitrogen, Life technologies, France) according to the manufacturer's instructions.

Deconjugation procedure and solid-phase extraction. Samples (0.5 ml) of cell culture media were treated for 2 h at 37°C with 200 U β -glucuronidase in 0.5 ml of 0.2 M acetate buffer; control samples were incubated with buffer alone. Each sample was then acidified to pH 4.5, received carbamazepin as internal standard (Zhu et al. 1999) and was passed through a C18 Sep-Pak cartridge (Waters, Milford, MA, USA) pre-conditioned with methanol and acetate buffer. After washing with acetate buffer, resveratrol and/or its metabolites were eluted with 2 ml of methanol. After evaporation, they were redissolved in ethanol for analysis.

HPLC analysis. Resveratrol assays were performed on a reverse-phase Nucleosil C18 column (250 x 4,6 mm, 5 μm) from Altech in a Waters 625-LC system. Compounds were eluted from the column with a gradient containing water and acetonitrile. Solvents were delivered according to Adrian et al. (2000). The UV detector (Waters 486) was set at 306 nm. Resveratrol amounts were quantified with a SP4400 ChromJet integrator (Spectra-Physics).

Mass spectrometry analysis. Resveratrol incubations (30 μM for 10 h) were performed in medium containing only 1% serum to minimize background due to serum constituents. Continuous infusion was performed on an Esquire mass spectrometer (Bruker Daltonik, Bremen, Germany) equipped with an ion-trap analyzer, APCI source and Bruker Daltonics Esquire LC4.5 data analysis software. Calibration of the mass spectrometer was achieved by injection of resveratrol. Spectra were recorded in the negative ion mode.

Quantitative Real-time PCR. SYBR Green PCR Mix (Biorad) and the iCycler thermocycler (Biorad) were used to detect the real-time quantitative PCR products of reverse-transcribed cDNA samples according to the manufacturer's instructions. The incubation conditions were as follows: 95°C for 3 min, followed by 40 cycles (95°C for 15 sec., 60°C annealing for 1 min). Expression levels of human phase II enzymes and housekeeping genes, β 2microglobulin, glyceraldehyde-3-phosphate dehydrogenase and porphobilinogen deaminase mRNAs were determined by using specific primers (Congiu et al., 2002). The Relative Expression Software Tool - Multiple Condition Solver (REST-MCS ©- version 2) was used to calculate the relative expression of target genes mRNA in real-time PCR using Pair Wise Fixed Reallocation Randomization Test© (Pfaffl et al., 2002). The mathematical model used is based on the mean crossing point deviation between sample and control group of target gene, normalized by the mean crossing point deviation of reference genes. Specific amplification efficiencies are included in the correction of the quantification ratio. Results are expressed as means $\pm$ standard error (SE) from duplicate PCR determinations of triplicate six-well plates from three independent experiments for each set of conditions tested. Significant differences between groups were analyzed by using REST-MC© test with 2000 randomization iterations.

Flow cytometry analyses. HepG2 cells were seeded into six-well plates at 500,000 per well. They were treated 24 h after seeding with resveratrol for 24 or 48 h. They were subsequently treated as previously described (Delmas et al., 2003). The used primary antibodies were mouse anti-ST1E1 (Calbiochem, VWR international SAS), mouse anti-UGT1A1, mouse anti-UGT2B7 (Gentest, BD Biosciences) or isotype-matched controls (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). The second antibody was a fluorescein isothiocyanate-labeled anti-mouse IgG (Jackson ImmunoResearch Laboratories). Simultaneously, a non-relevant isotype-matching Ab was used as negative control. Analyses were performed on a logarithmic scale consisting of 4 decades of log on a GALAXY cytometer (Partec, Münster, Germany) at excitation and emission wavelengths of 488 nm and 590 nm, respectively. For each sample, 10,000 cells were acquired with the FlowMax software (Partec), and data registered under the fcs format were further analyzed with Expo 32 software (Beckman-Coulter, Miami, USA).

Tritiated resveratrol uptake measurement. HepG2 cells were incubated at 37°C with 1 μ M of tritiated resveratrol, with or without 50 μ M of MK571. The labeled medium was removed and the cell wells were washed two times with a cold PBS buffer. After addition of 400 μ l per well of lysis buffer (0.1% SDS, 0.1 M NaOH, 2% Na₂CO₃), the cell homogenates were transferred into flasks and cell-associated radioactivity was counted in a Flow Scintillation Analyzer Perkin-Elmer (Life Sciences Inc., Welleley, MA, USA). Data were analyzed with a Varian Star chromatography workstation software version 5.5.

RESULTS AND DISCUSSION

Resveratrol metabolism: time-course and autoinduction. HepG2 cells were incubated with 10 μ M of resveratrol for different times. Cell culture media were then collected, treated or not with β -glucuronidase, extracted and analyzed by HPLC (Fig. 1B). The amount of resveratrol conjugated and released in the medium was indirectly determined by difference between untreated media (unconjugated resveratrol) and enzyme-treated media (total). The proportion of conjugated resveratrol was of 20% after 2 h of incubation, increased to 50 % at 4 h and reached almost 100% at 8 h. Moreover the initial amounts of resveratrol were always recovered after enzymatic treatment, meaning that there were no other metabolites than glucuronides and/or sulfates (the β -glucuronidase used for these experiments having also a sulfatase activity).

To search for a possible inducibility of phase II enzymes by resveratrol, we studied the effect of a pre-treatment of the cells with resveratrol on its own metabolism. For this purpose, cells were pre-treated either with 10 μ M resveratrol for 2-fold 24 h (T48) or only for the last 24 h (T24) or cultured for 48 h without resveratrol (T0). After these 48 h, the cells were

incubated again with 10 μ M resveratrol. Unconjugated resveratrol remaining in the media after 2 h or 4 h of incubation was quantified by HPLC (Fig. 1C). The percentage of unconjugated resveratrol was significantly lower in cells pre-treated for 48 h; it fell from 45% to 30 % after 2 h incubation and from 16% to 8 % after 4 h incubation. These decreases expressed an acute resveratrol metabolism in cells pre-treated for 48 h with resveratrol and consequently corresponded to an autoinduction of this metabolism.

Ion-trap mass spectrometry analysis of resveratrol metabolites. We performed an analysis of extracted cell culture media by direct infusion to allow not only the determination of metabolite class but also the discrimination between mono- and di-derivatives as well as mixed derivatives. Five compounds were found only in the media of resveratrol-treated cells and identified thanks to their characteristic fragmentation (Table I). Unconjugated resveratrol was identified by comparison to standard resveratrol. Resveratrol monosulfate and resveratrol disulfate were identified thanks to the characteristic loss of a fragment of 80 (SO_3 group). Two isomeric forms are a priori possible for the mono-derivative: resveratrol-3-sulfate and resveratrol-4'-sulfate, as well as two isomeric forms for the di-derivative: resveratrol-3,4'-disulfate and resveratrol-3,5-disulfate (see formula Fig.1A). These different metabolites were found in plasma of Wistar rats after oral administration of resveratrol Wenzel et al., 2005). Contrary to this study, we have not detected resveratrol-trisulfate in our analysis.

Our results are in accordance with a study on healthy volunteers (Walle et al., 2004), which reported that sulfoconjugates are the main urine excreted metabolites in humans (twice more than the glucuronconjugates) and that resveratrol conjugation occurs rapidly, mostly as sulfate conjugates, after i.v. resveratrol infusion. Although resveratrol glucuronidation was shown in human liver (De Santi et al., 2000b, Vitaglione et al., 2005), our analysis did not evidence any glucuronide. They were not lost during the solid phase extraction; we have indeed found the same recovery of radioactivity after extraction on SepPak cartridges of media incubated with radiolabeled resveratrol in presence or in absence of cells, meaning that all the metabolites eluted in the methanolic phase (data not shown). We may suggest that in our experimental conditions sulfation was predominant over glucuronidation; resveratrol sulfation was characterized by a smaller K_M (0,63 μ M, De Santi et al., 2000 b) than glucuronidation (150 μ M, De Santi, 2000a). Therefore, it should exist a competition between the two enzymes for resveratrol metabolism, so that high-affinity sulfation pathway occurs exclusively at moderate resveratrol concentrations, not sufficient to saturate this pathway.

Induction of phase II enzymes. To explain the autoinduction of resveratrol metabolism, we searched for the induction of phase II enzymes. Induction of mRNA levels was determined by quantitative RT-PCR in HepG2 cells pre-treated for 24 h with variable concentrations of resveratrol. Two UGT isoforms were tested, UGT1A1 and UGT2B7 and one sulfotransferase isoform, ST1E1 (Fig.2A). For these three enzymes, we observed an induction of mRNA level with a maximum for a pre-treatment with 10 μ M resveratrol. UGT2B7 appeared to be the more induced with a 5-fold increase in mRNA expression after pre-treatment with 10 μ M resveratrol.

To determine if the induction of their mRNA levels is correlated with an increase in their protein amounts, we measured the expression of UGT1A1, UGT2B7 and ST1E1 in HepG2 cells untreated or treated with 10 or 30 μ M resveratrol for 24 and 48 h. After treatment, the cells were stained with the appropriate Abs, and then analyzed by flow cytometry (Fig.2B). Resveratrol at 10 μ M induced a weak increase in UGT2B7 expression at 24 h (+11%). An increase more important was observed at 48 h with 30 μ M (+65 %). Concerning the UGT1A1 expression, we noted +24% at 10 μ M for 24 h of treatment and +37% for 48 h. At 30 μ M resveratrol, we observed an increase of 25% at 24 h and of 29% at 48 h. We observed also an increase in ST1E1 expression of 49% at 24 h and +14% at 48 h with 10 μ M of resveratrol. and of 14% at 24 h and 23% at 48 h with 30 μ M of resveratrol. Therefore, a protein induction was observed for these three enzymes, generally greater after 48 h of pre-treatment. These results were in accordance with those of RT-PCR: generally, protein induction after 48 h of

pre-treatment correlated well with the mRNA level induction after 24 h of pre-treatment. The induction of ST1E1 correlates well with the autoinduction of resveratrol metabolism, meaning that ST1E1 activity is increased, this isoform being involved in resveratrol sulfation in human liver (Miksits et al., 2005). Moreover, we have found the induction of UGT1A1 responsible for glucuronidation of *trans*-resveratrol and UGT2B7, which presents an activity, restricted to *cis*-resveratrol (Aumont et al., 2001). UGT1A1 inducibility was shown in vivo in rat liver, but with treatments at high doses of resveratrol (Hebbar et al., 2005).

Impairment of resveratrol efflux by MRP transport inhibitor. The time-course of resveratrol uptake by HepG2 cells was monitored by the determination of intracellular radioactivity after cell incubations at 37°C with 1 µM of radiolabeled resveratrol. The various incubation times were chosen according to our previous experiments showing that intracellular radioactivity increases rapidly to reach a maximum at 10 minutes (Lançon et al., 2004). The same fast resveratrol uptake was observed in control cells as well as in cells treated with 50 µM MK-57 (Fig.3). Conversely, the decrease in intracellular radioactivity in MK571 treated cells was delayed, compared to control cells. After 1 h of incubation, the intracellular radioactivity in MK571 treated cells was 2.8-fold higher than in control cells; it was still 2-fold higher after 2 h of incubation. These experiments indicated that MK571 did not affect resveratrol influx but impaired resveratrol efflux. MK571 being known to inhibit MRPs, our results show for the first time the implication of these pumps in the efflux of conjugated resveratrol from liver. By also using MK571, Henry et al. (2005) have reported the implication of MRP2/MRP3 in human intestinal Caco2 cell line transport of conjugated resveratrol. Moreover, it was shown that resveratrol impairs ochratoxine A intestinal efflux in a similar manner as MK571, suggesting a competitive inhibition of MRP-2 by resveratrol (Sergent et al., 2005). Conversely, we have not shown any effect of verapamil on resveratrol efflux, excluding the implication of the MDR glycoprotein P (data not shown). The inhibition of MRPs by resveratrol may be interesting for chemotherapeutic strategies. Indeed, it has been shown that resveratrol acts in synergy with death receptor ligands and may be a sensitizing agent to chemotherapeutic drugs (Delmas et al., 2004). Therefore, a competitive inhibition of MRP-2 by resveratrol, used in association with cytotoxic drugs, would contribute to reduce therapeutic failures in the treatment of chemoresistant cancers.

ACKNOWLEDGEMENTS

We acknowledge Etienne Semon for mass spectrometry analysis.

REFERENCES

- Adrian M, Jeandet P, Douillet-Breuil AC, Tesson L and Bessis R (2000) Stilbene content of mature *Vitis vinifera* berries in response to UV-C elicitation. *J Agric Food Chem* **48**:6103-6105.
- Aumont V, Krisa S, Battaglia E, Netter P, Richard T, Merillon JM, Magdalou J and Sabolovic N. (2001) Regioselective and stereospecific glucuronidation of *trans*- and *cis*-resveratrol in hum. *Arch Biochem Biophys* **393**:281-289.
- Congiu M, Mashford ML, Slavin JL and Desmond PV (2002) UDP glucuronosyl-transferase mRNA levels in human liver disease. *Drug Metab Dispos* **30**:129-134.
- De Santi C, Pietrabissa A, Spisni R, Mosca F and Pacifici GM (2000a) Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. *Xenobiotica* **30**:609-617.
- De Santi C, Pietrabissa A, Mosca F and Pacifici GM (2000b) Glucuronidation of resveratrol, a natural product present in grapes and wine, in the human liver. *Xenobiotica* **30**:1047-1054.
- Delmas D, Rebe C, Lacour S, Filomenko R, Athias A, Gamber P, Cherkaoui-Malki M, Jannin B, Dubrez-Daloz L, Latruffe N and Solary E. (2003) Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death inducing signaling complex in colon cancer cells. *J Biol Chem* **278**:41482-90.
- Delmas D, Rebe C, Micheau O, Athias A, Gamber P, Grazide S, Laurent G, Latruffe N and Solary E (2004) Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. *Oncogene* **23** :8979- 8986.
- Delmas D, Jannin B and Latruffe N (2005) Resveratrol preventing properties against vascular alterations and ageing. *Mol Nutr Food Res*. **49**:377-395.
- Delmas D, Lancon A, Colin D, Jannin B and Latruffe N (2006) Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. *Curr Drug Target* **7**:423-442.
- Hebbar V, Shen G, Hu R, Kim BR, Chen C, Korytko PJ, Crowell JA, Levine BS and Kong AN. (2005) Toxicogenomics of resveratrol in rat liver. *Life Sci* **76**:2299-2314.
- Henry C, Vitrac X, Decendit A, Ennamany R, Krisa S and Merillon JM (2005) Cellular uptake and efflux of *trans*-piceid and its aglycone *trans*-resveratrol on the apical membrane of human intestinal Caco-2 cells. *J Agric Food Chem* **53**:798-803.
- Kaldas MI, Walle UK and Walle T (2003) Resveratrol transport and metabolism by human intestinal Caco-2 cells. *J Pharm Pharmacol* **55**:307-312.
- Lançon A, Delmas D, Osman H, Thénot J-P, Jannin B and Latruffe N (2004) Human hepatic cell uptake of resveratrol: involvement of both passived diffusion and carrier-mediated process. *Biochem Biophys Res Commun* **316**:1132-1137.

- Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP and Ducharme MP (2002) Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. *J Pharmacol Exp Ther* **302**:369-373.
- Miksits M, Maier-Salamo A, Aust S, Thalhammer T, Teznicek G, Kunert O, Haslinger E, Szeleres T and Jaeger X (2005) Sulfation of resveratrol in human liver : evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. *Xenobiotica* **35** :1101-1119.
- Pfaffl MW, Horgan GW and Dempfle L (2002) Relative expression software tool (REST) for groupe-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucleic Acids Res* **30**:e36.
- Sergent T, Garsou S, Schaut A, De Saeger S, Pussemier L, Van Peteghem C, Larondelle Y and Schneider YJ (2005) Differential modulation of ochratoxin A absorption across Caco-2 cells by dietary polyphenols, used at realistic intestinal concentrations. *Toxicol Lett* **159**:60-70.
- Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi PP, Fogliano V and Marchelli R (2005) Bioavailability of *trans*-resveratrol from red wine in humans. *Mol Nut Food Res* **49**:495-504.
- Walle T, Hsieh F, DeLegge MH, Oatis JE Jr and Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. *Drug Metab Dispos* **32**:1377-1382.
- Wenzel E and Somoza V (2005) Metabolism and bioavailability of *trans*-resveratrol. *Mol Nut. Food Res* **49**: 472-481.
- Wenzel E, Soldo T, Erbersdobler H and Somoza V (2005) Bioactivity and metabolism of *trans*-resveratrol orally administered to Wistar rats. *Mol Nut Food Res* **49**:482-494.
- Zhu Z, Klironomos G, Vachereau A, Neirinck L and Goodman DW (1999) Determination of *trans*-resveratrol in human plasma by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl.* **724**:389-392

FOOTNOTES

This study was supported by the "Conseil Régional de Bourgogne", BIVB and the "Ligue Bourguignonne contre le Cancer".

FIGURES & TABLE

FIG. 1. Resveratrol metabolism: time course and autoinduction. A, chemical structure of resveratrol and resveratrol sulfates; B, time course of conjugation. HepG2 cells were treated for the indicated times with 10 μM resveratrol. Collected culture media were extracted and analyzed by HPLC. They were treated either at 37°C for 1 h with β -glucuronidase for the quantification of total resveratrol (striped bar) or with buffer alone for the quantification of unconjugated resveratrol (gray bar). The difference between these two values gave the percentage of conjugated resveratrol (black bar). C, autoinduction of resveratrol metabolism. HepG2 cells were pre-treated for 0 h (T0), 24 h (T24), or 48 h (T48) with 10 μM resveratrol. Cell culture media were discarded and the cells were exposed again to 10 μM resveratrol for 2 h (top) or 4 h (bottom). The amount of unconjugated resveratrol was determined by HPLC and expressed as percentage of the amount of resveratrol added to medium at the beginning of the incubations. Values represent the mean $\pm$ S.D. of triplicate samples from two individual experiments (* corresponds to $p < 0.05$, ** to $p < 0.01$, and *** to $p < 0.001$).

Fig. 2. Resveratrol induces phase II enzyme expression in human hepatoblastoma cells. A, HepG2 cells were either untreated or treated with the indicated concentrations (micromolar) of resveratrol during 24 h of treatment. Real-time PCR shows mRNA level of UGT1A1, UGT2B7, and ST1E1 in HepG2 cells. Bars represent the increase in HepG2 cells as a -fold change of control (*, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$). B, flow cytometry analysis of UGT1A1, UGT2B7, and ST1E1 expression in HepG2 cells untreated (black line) or treated (gray line), under the same conditions as in A, with 10 μM resveratrol (R10) or 30 μM resveratrol (R30) for the indicated time. The percentages represent the relative increase in expression compared with control. One representative of three independent experiments is shown.

Fig. 3. Inhibition of resveratrol efflux by MK571. HepG2 cells were incubated in the presence of 1 μM labeled resveratrol (specific activity 3.7 GBq/mmol) at 37°C for the indicated times, in the absence (gray triangles) or presence (open squares) of 50 μM MK571. At the end of each incubation period, the labeled medium was removed and after fast washing and cell lysis, the amount of resveratrol remaining in the cells was evaluated from the cell-associated radioactivity determined by counting in a liquid scintillation analyzer. Data points are from a representative experiment among three, and each point represents the mean of two determinations.

TABLE 1

Negative ion atmospheric pressure chemical ionization-tandem mass spectrometry on resveratrol metabolites

The numbers in parentheses indicate the relative intensity.

MS1 Ions (m/z) [M - H] ⁻	MS2 Product Ions		MS3 Product Ions (m/z)	Identification
	m/z	Fragment loss		
227	185 (100)	[M - H - 42] ⁻		(Standard resveratrol)
	159 (48)	[M - H - 68] ⁻		
	143 (27)	[M - H - 84] ⁻		
	185 (100)	[M - H - 42] ⁻		
227	159 (48)	[M - H - 68] ⁻		Resveratrol
	143 (27)	[M - H - 84] ⁻		
	243 (8)	[M - H - 64] ⁻		
	227 (100)	[M - H - 80] ⁻		
307	265 (100)	[M - H - 64] ⁻	185,159,143	Resveratrol monosulfate
329	249 (60)	[M - H - 80] ⁻		Sodium resveratrol monosulfate
	242 (72)	[M - H - 64 - 23] ⁻		
	345 (11)	[M - H - 64] ⁻		
409	329 (100)	[M - H - 80] ⁻	265,249,242	Sodium resveratrol disulfate
	306 (12)	[M - H - 80 - 23] ⁻		